Sun Pharma rises as its arm launches CEQUA for Canadians living with dry eye disease
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Sun Pharmaceutical Industries is currently trading at Rs. 813.15, up by 6.15 points or 0.76% from its previous closing of Rs. 807.00 on the BSE.
The scrip opened at Rs. 806.40 and has touched a high and low of Rs. 817.05 and Rs. 791.30 respectively. So far 78715 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 871.00 on 13-Jan-2022 and a 52 week low of Rs. 550.70 on 28-Jan-2021.
Last one week high and low of the scrip stood at Rs. 842.45 and Rs. 785.00 respectively. The current market cap of the company is Rs. 194598.06 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 33.99% and 11.53% respectively.
Sun Pharmaceutical Industries’ wholly owned subsidiary -- Sun Pharma Canada Inc has launched CEQUA, a new treatment for Canadians living with dry eye disease. CEQUA (cyclosporine ophthalmic solution 0.09% w/v), a calcineurin inhibitor immunomodulator, is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration.
This launch is an important milestone for Sun Pharma as company expand its ophthalmics portfolio into Canada and it demonstrates its commitment to providing innovative medicines to support patient and physician choice.
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
